Brain injection trial hopes to tame Parkinson's

NCT ID NCT05822739

Completed Disease control Sponsor: Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a gene therapy called BBM-P002 in 10 people with advanced Parkinson's disease. The treatment is given as a single injection directly into the brain during a neurosurgical procedure. The main goal was to check safety, but researchers also looked for signs of improvement in symptoms and medication use. Because it is a very small, early trial, results are preliminary and cannot yet confirm whether the therapy works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BBM-P002 (a gene therapy injected into the brain)
What this could lead to: If it works, this could point toward a new way to control Parkinson's symptoms and reduce medication needs.
What could go wrong: This is a very early, small study with only 10 people. It is designed mainly to check safety, not prove effectiveness. The treatment involves brain surgery, which carries risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE

Contacts and locations

Locations

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China
Xiangya Hospital of Central South University

Changsha, Hunan, 410008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.